Modi Shan P, Klipa Ilija, Cronin Melissa A, Lukens Jennifer E, Hollowell Leelyn R, Stawski Tracie A, Criste Taylor J, Nissley Trevor J, Ramirez Philip, VanDyck Tyler J
Cardiovascular Institute, Allegheny Health Network, Pittsburgh, PA, USA.
Perfusion. 2025 Jul;40(5):1124-1128. doi: 10.1177/02676591241290402. Epub 2024 Oct 4.
IntroductionThe mobilization and ambulation of patients with severe cardiogenic shock supported with peripheral veno-arterial extracorporeal membrane oxygenation (pVA-ECMO) and concomitant femoral intra-aortic balloon pump (IABP) support is not well-described. This technical paper describes an ambulation protocol to prevent deconditioning in this critically ill patient population.MethodsA protocol for the ambulation of patients with pVA-ECMO and concomitant IABP support was created in December 2022 and implemented at a single center. To initiate ambulation, patients were initially placed in a vertical position utilizing the VitalGo Total Lift Bed (VitalGo Systems, Miramar, FL) with mechanical circulatory support device monitoring performed by a critical care multidisciplinary team. Retrospective analysis of successfully ambulated patients was performed from December 2022 to January 2024.ResultsA total of 35 patients out of 112 patients with ECMO support were ambulated in the study period. Four of these patients had pVA-ECMO with concomitant IABP support with this cohort completing a total of 11 sessions during the study period. Patients ambulated an average of 200 feet per session without any adverse events, including cannula and balloon pump migration or displacement. Three of the four patients studied were either bridged to an advanced therapy including orthotopic heart transplant or durable left ventricular assist device or were discharged.ConclusionA protocol for ambulation of CS patients with pVA-ECMO support and concomitant femoral IABP support is feasible and can safely be implemented in this critically ill patient population. Further multicenter studies are necessary to determine the overall impact of ambulation on patient outcomes.
引言
对于接受外周静脉 - 动脉体外膜肺氧合(pVA - ECMO)支持并同时使用股动脉主动脉内球囊反搏(IABP)的严重心源性休克患者,其活动和行走情况尚未得到充分描述。本技术论文描述了一种活动方案,以防止这一危重症患者群体出现身体机能衰退。
方法
2022年12月制定了一项针对接受pVA - ECMO支持并同时使用IABP的患者的活动方案,并在单一中心实施。为开始活动,患者最初使用VitalGo全升降床(VitalGo Systems,米拉马尔,佛罗里达州)置于垂直位置,由重症多学科团队进行机械循环支持设备监测。对2022年12月至2024年1月成功进行活动的患者进行回顾性分析。
结果
在研究期间,112例接受ECMO支持的患者中有35例进行了活动。其中4例患者接受pVA - ECMO并同时使用IABP支持,该队列在研究期间共完成了11次活动。患者每次活动平均行走200英尺,未出现任何不良事件,包括插管和球囊泵移位或脱位。所研究的4例患者中有3例要么过渡到包括原位心脏移植或耐用左心室辅助装置在内的高级治疗,要么出院。
结论
对于接受pVA - ECMO支持并同时使用股动脉IABP支持的心源性休克患者,活动方案是可行的,并且可以在这一危重症患者群体中安全实施。需要进一步的多中心研究来确定活动对患者预后的总体影响。